Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack -

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Information type: Other primary research
Source: Journal of the American Medical Association
Specialities: Stroke
Summary
Chinese study (n=2933) found after day 90 follow-up, clopidogrel-aspirin (CA) reduced the rate of new stroke in the non-carriers but not in carriers of loss-of-function alleles vs aspirin alone.
UKMi comment
The study found new stroke among non-carriers occurred in 41 patients [6.7%] on CA vs. 74 patients [12.4%] on aspirin (HR 0.51 [95% CI, 0.35-0.75]). Comparatively, new stroke among carriers occurred in 80 patients [9.4%] on CA vs. 94 [10.8%] on aspirin (HR 0.93 [95% CI, 0.69 to 1.26]).
Related links: